Latest Content

FDA Grants Jemperli Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer

December 21st 2024, 7:00pm

By Ryan Scott

Article

Jemperli received breakthrough therapy designation by the FDA for locally advanced mismatch repair deficient/microsatellite instability-high rectal cancer.

Darzalex Regimen May Improve MRD Responses in Multiple Myeloma

December 21st 2024, 3:00pm

By Kristie L. Kahl

Article

Patients newly diagnosed with multiple myeloma who are transplant ineligible or deferred may benefit from receiving a Darzalex treatment combination.

How to Self Advocate When Insurance Says No to Cancer Treatment Coverage

December 20th 2024, 8:00pm

By Ashley Chan

Article

When insurance denies coverage of cancer treatment, patients with cancer don’t need to take no for an answer, an expert explained.

FDA Approves Braftovi Plus Erbitux and Chemo for Metastatic Colorectal Cancer Subset

December 20th 2024, 7:03pm

By Darlene Dobkowski, MA

Article

Braftovi received accelerated approval with Erbitux and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

Reflecting on Cancer During a Christmas Morning Run

December 20th 2024, 6:00pm

By Brian Sluga

Article

A reflective Christmas morning run, following a cancer diagnosis, inspires profound gratitude for life and a renewed commitment to living a meaningful life.

NFL Star Randy Moss Undergoing Cancer Treatment, Montell Jordan Shares Update and More

December 20th 2024, 4:00pm

By Alex Biese

Article

From a Pro Football Hall of Famer announcing his diagnosis to an R&B star’s latest update, here’s what’s happening in the cancer space this week.

Zejula-Jemperli Combo Shows Promising Responses in Breast Cancer Subset

December 20th 2024, 2:00pm

By Ariana Pelosci

Article

A combination of presurgical Zejula and Jemperli showed promising treatment responses in certain patients with ER-positive, HER2-negative breast cancer.

Enhertu May Help Preserve Quality of Life in HER2-Positive Breast Cancer

December 19th 2024, 10:00pm

By Kyle Doherty

Article

Treatment with Enhertu showed favorable outcomes regarding health-related quality of life in patients with HER2-positive breast cancer, regardless of brain metastases.

Targeting Multiple Pathways Improves Outcomes in Some With Metastatic Breast Cancer

December 19th 2024, 8:00pm

By Darlene Dobkowski, MA

Video

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, HER2-positive metastatic breast cancer.

Embracing Gratitude During the Holidays

December 19th 2024, 6:00pm

By Tamron Little

Article

A survivor shares tips on ways to practice gratitude the holiday season.

UGN-102 May Improve Quality of Life Versus Surgery in Bladder Cancer

December 19th 2024, 4:00pm

By Ashley Chan

Article

Treatment with UGN-102 has shown promise as a non-surgical alternative when compared with a surgical approach for certain patients with bladder cancer.

What is Follicular Lymphoma and Why Are Better Treatments Needed?

December 19th 2024, 2:00pm

By Alex Biese

Video

CURE® spoke with an expert about follicular lymphoma, a disease that is still considered incurable.

Ryoncil Receives FDA Approval for Children With GVHD

December 18th 2024, 10:45pm

By Darlene Dobkowski, MA

Article

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

Polycythemia Vera: Overview

December 18th 2024, 10:01pm

By Julie Huynh-Lu, P.A.

Video

A panelist discusses how polycythemia vera (PV) is a rare myeloproliferative neoplasm (MPN) characterized by excessive red blood cell production, primarily affecting older adults with JAK2 mutations, and while it can be managed with treatment, patients face increased risks of blood clots and potential progression to more serious conditions.

FDA Approves Ensacove for ALK-Positive NSCLC

December 18th 2024, 9:01pm

By Alex Biese

Article

The Food and Drug Administration has approved Ensacove for patients with ALK-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK-inhibitor.